Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 12/20 | 0.77 |
| ▸ | MEN1 known ✓ | O00255 | 5/20 | 0.77 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 0.77 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.55 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 3/20 | 0.55 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.55 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.55 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.55 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.55 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.55 |
| ▸ | IDH1 known ✓ | O75874 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.77 |
| ▸ | TP53 | P04637 | 4/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL17164706 | 1.00 | ESR1 (0.77) | ESR1KMT2AMEN1ESR2TP53 | |
| Citric Acid SCHEMBL17164692 | 0.97 | ESR1 (0.71) | ESR1KMT2AMEN1ESR2TP53 | |
| Citric Acid SCHEMBL17164712 | 0.97 | ESR1 (0.71) | ESR1KMT2AMEN1ESR2TP53 | |
| Citric Acid SCHEMBL17164696 | 0.89 | KMT2A (0.74) | ESR1KMT2AMEN1ESR2TP53 | |
| Citric Acid SCHEMBL17164709 | 0.89 | KMT2A (0.74) | ESR1KMT2AMEN1ESR2TP53 | |
| Tamoxifen SCHEMBL5328781 | 0.87 | ESR1 (1.00) | ESR1KMT2AMEN1ESR2TP53 | |
| Tamoxifen SCHEMBL10336277 | 0.87 | ESR1 (1.00) | ESR1KMT2AMEN1ESR2TP53 | |
| Tamoxifen SCHEMBL4019370 | 0.87 | ESR1 (1.00) | ESR1KMT2AMEN1ESR2TP53 | |
| Tamoxifen SCHEMBL17164701 | 0.87 | ESR1 (1.00) | ESR1KMT2AMEN1ESR2TP53 | |
| Tamoxifen SCHEMBL26077 | 0.87 | ESR1 (1.00) | ESR1KMT2AMEN1ESR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4341283-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-3551197-B1 | CHIMERIC TRANSCRIPTION FACTOR VARIANTS WITH AUGMENTED SENSITIVITY TO DRUG LIGAND INDUCTION OF TRANSGENE EXPRESSION IN MAMMALIAN CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230242936-A1 | DUAL PROMOTER SYSTEMS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230130938-A1 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4149966-A1 | DUAL PROMOTER SYSTEMS | Seattle Children's Hospital (DBA Seattle Children's Research Institute) (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220411805-A1 | CHIMERIC TRANSCRIPTION FACTOR VARIANTS WITH AUGMENTED SENSITIVITY TO DRUG LIGAND INDUCTION OF TRANSGENE EXPRESSION IN MAMMALIAN CELLS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2022-12-29 | — | — | US | disclosed |
| WO-2022241289-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-11-17 | — | — | WO | disclosed |
| US-11458167-B2 | Bispecific CAR T-cells for solid tumor targeting | SEATTLE CHILDREN'S HOSPITAL (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3129399-B1 | DRUG RELATED TRANSGENE EXPRESSION | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210085719-A1 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2021-03-25 | — | — | US | disclosed |
| US-10919950-B2 | Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment | SEATTLE CHILDREN'S HOSPITAL (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200215108-A1 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2020-07-09 | — | — | US | disclosed |
| US-20200181624-A1 | CHIMERIC TRANSCRIPTION FACTOR VARIANTS WITH AUGMENTED SENSITIVITY TO DRUG LIGAND INDUCTION OF TRANSGENE EXPRESSION IN MAMMALIAN CELLS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2020-06-11 | — | — | US | disclosed |
| US-10266592-B2 | Drug regulated transgene expression | SEATTLE CHILDREN'S HOSPITAL (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190016776-A1 | TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2019-01-17 | — | — | US | disclosed |
| EP-3331920-A1 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | Seattle Children's Hospital, dba Seattle Children's Research Institute (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20170152297-A1 | DRUG REGULATED TRANSGENE EXPRESSION | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2017-06-01 | — | — | US | disclosed |
| WO-2017027291-A1 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2017-02-16 | — | — | WO | disclosed |